Journal article icon

Journal article

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome

Abstract:

Richter syndrome (RS) is associated with chemotherapy resistance and a poor historical median overall survival (OS) of 8–10 months. We conducted a phase II trial of standard CHOP-21 (cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 d) with ofatumumab induction (Cycle 1: 300 mg day 1, 1000 mg day 8, 1000 mg day 15; Cycles 2–6: 1000 mg day 1) (CHOP-O) followed by 12 months ofatumumab maintenance (1000 mg given 8-weekly for up to six cycles). Forty-three patients were recruit...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1111/bjh.14177

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS, CSM
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD
Clifford, R More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD
Expand authors...
National Institute of Health Research More from this funder
Publisher:
John Wiley & Sons Ltd Publisher's website
Journal:
British Journal of Haematology Journal website
Volume:
175
Issue:
1
Pages:
43–54
Publication date:
2016-07-05
DOI:
EISSN:
1365-2141
ISSN:
0007-1048
URN:
uuid:34244807-a3dc-4aaf-8b76-8eec509388e7
Source identifiers:
632442
Local pid:
pubs:632442

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP